as discussed above, proof of concept has been achieved for JMJD2B, and different studies have also shown that JMJD2C is required for growth of various cancer cell lines like prostate carcinoma [62], breast carcinoma [122], squamous cell carcinoma [130] and diffuse large B cell lymphoma [131]. Here, KDM4C is linked to squamous cell carcinoma.